Biotech News

Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra

Madrigal (MDGL)MadrigalCompany update

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced results from multiple real-world studies of Rezdiffra presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® , taking place Nov. 5–9 in Denver.

Related news

Madrigal

MASH-Focused Biopharmaceutical Company Madrigal Pharmaceuticals is focused on metabolic dysfunction-associated steatohepatitis, a progressive liver disease that can lead to cirrhosis, liver failure, cancer, and transplantation. The company is building a specialized commercial and clinical-development organization around therapies that...

Recent company news

Stock data

Close
396.74 USD
Market cap
10.44B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States